Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-172 in Hyperphosphatemia Patients on Hemodialysis
NCT07285291Phase 3Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TS-172 in hyperphosphatemia, sponsored by Taisho Pharmaceutical. Started Jan 2026; status: recruiting.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT07285291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285291.